Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
May 02 2024 - 7:30AM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that it will report its first quarter 2024
financial results on Thursday, May 9, 2024 and will provide a
business update.
Altimmune management will host a conference call
at 8:30 am E.T. on May 9 to discuss financial results and provide a
business update. The conference call will be webcast live on
Altimmune’s Investor Relations website at
https://ir.altimmune.com/investors.
Participants who would like to join the call may
register here to receive the dial-in numbers and unique PIN to
access the call. Shortly after the call, a replay will be available
on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
peptide-based therapeutics. The Company is developing pemvidutide,
a GLP-1/glucagon dual receptor agonist for the treatment of obesity
and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Company Contact:Richard
Eisenstadt Chief
Financial Officer
Phone:
240-654-1450 reisenstadt@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com Julia WeilmanBurns McClellanPhone:
646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke
CommsPhone: 619-826-4657Danielle.cantey@inizioevoke.com
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Aug 2023 to Aug 2024